MeVis Medical Solutions AG (M3V) Fair Value & Analysis
Healthcare · DE · Market cap €42.2M
Fair value as of: Jun 24, 2026
Analysis
MeVis Medical Solutions AG (M3V) currently trades at €23.60, while our model-based Fair Value estimate is €24.48 — implying the stock looks roughly 3.7% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
MeVis Medical Solutions AG develops software for recording, analyzing, and evaluating image data to manufacturers of medical devices, providers of medical IT platforms, and clinical end customers in the United States and Europe. The company provides image-based early detection and diagnosis of epidemiologically important diseases, such as breast, lung, liver, and neurological diseases. It also offers X-ray based radiography procedures, including computed tomography, mammography/digital tomosynthesis, magnetic resonance imaging, and digital sonography; as well as provides services in the field of software programming for medical technology companies, which comprise provision of software developers, product and project managers, application specialists, and test engineers. In addition, the company provides three-dimensional technical visualizations; and interactive online training to enhance the diagnostic skills of clinicians; and internet-based special applications in teleradiology.…
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is MeVis Medical Solutions AG (M3V) undervalued?
What is the fair value of M3V?
What is the quality score of M3V?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.